Authors
Hoang V.B., Tyrenko V.V., Sherbatyuk О.V., Bologov S.G.
S.M. Kirov Military medical academy, St. Petersburg
Abstract
Despite the continuous change in the concept of atherosclerosis, dyslipidemia remains a leading risk factor for the development of atherosclerotic diseases. This review article presents current data on the problem of lipid profile control, the main strategies for lipid-lowering therapy, the relevance of the use of subtilisin/kexin type 9 proprotein convertase inhibitors in patients with very high and extreme risk of cardiovascular complications.
Keywords: dyslipidaemia, extreme risk, inhibitors of proprotein convertase subtilisin/kexin type 9, strategy.
References
1. Kuranov AA, Baleev MS, Mitrofanova NN, Melnikov VL. Some aspects of the pathogenesis of atherosclerosis and risk factors for cardiovascular disease. Fundamental-research. 2014; 10-6: 1234-1238. (In Russ.)
2. Litovskij IA, Gordienko AV, Sotnikov AV. Controversial issues of pathogenesisand lipid-lowering therapy of atherosclerosis. Clinpharm-journal. 2019; 28(4): 10-23. (In Russ.) doi: 10.32756/0869-5490-2019-4-10-23.
3. Nelson K, Fuster V, Ridker PM. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2023; 82(7): 648-660. doi: 10.1016/j.jacc.2023.05.055.
4. Nidorf SM, Fiolet AT, Mosterd A, et al. Colchicine in patients with chronic coronary disease. New England journal of medicine. 2020; 383(19): 1838-1847. doi: 10.1056/nejmoa2021372.
5. Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomized trials. The Lancet. 2023; 401(10384): 1293-1301. doi: 10.1016/S0140-6736(23)00215-5.
6. Zueva IB, Baratashvili GG, Krivonosov DS, et al. The role of lipoprotein (a) in the development of cardiovascular events and the therapeutic potential. Arterial Hypertension. 2016; 22(3): 232-243. (In Russ.) doi: 10.18705/1607-419X-2016-22-3-232-243.
7. Vasiliev AG, Morozova KV, Brus ТV, et al. Тhe role of homocysteine metabolic disorders in pathological processes. Russian Biomedical Research. 2022. 7(1), 44-59. (In Russ.)
8. Chazova IE, Zhernakova YuV, Kislyak OA, et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Systemic Hypertension. 2022; 19(1): 5-22. (In Russ.) doi: 10.38109/2075-082X-2022-1-5-22.
9. Gordienko AV, Serdyukov DYu. Initial atherosclerosis: risk factors, diagnosis, prevention, treatment. St. Petersburg: SpetsLit. 2020. (In Russ.)
10. Golovko NN. The role of total antioxidant status in ischemic disease in women. News of the Russian Military Medical Academy. 2018; 37(1): 156-158. (In Russ.)
11. Uryeva EA, Sukhorukov VS, Vozdvizhenskaya ES, Novikova NN. Atherosclerosis: Hypotheses and theories. Russian Bulletin of Perinatology and Pediatrics. 2014; 59(3): 6-16. (In Russ.)
12. Tishko VV, Tyrenko VB, Kozlov KL, et al. Multidisciplinary approach to managing high-risk patients after repeated myocardial revascularization. Clinical Gerontologist. 2014; 20(9-10): 40-44. (In Russ.)
13. Aronov DM, Bubnova MG, Drapkina OM. Atherosclerosis pathogenesis from the perspective of microvascular dysfunction. Cardiovascular Therapy and Prevention. 2021; 20(7): 133-142. (In Russ.) doi:10.15829/ 1728-8800-2021-3076.
14. Baigent C, Keech A, Kearney P, et al. Efficacy and safety of cholesterol-lowering treatment–Authors’ reply. The Lancet. 2006; 367(9509): 470-471. doi: 10.1016/S0140-6736(06)68171-3.
15. Trialists C.T. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet. 2010; 376(9753): 1670-1681. doi: 10.1016/S0140-6736(10)61350-5.
16. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocrine Practice. 2017; 23: 1-87. doi: 10.4158/EP171764.APPGL.
17. Sergienko IV, Shestakova MV, Boystov SA, et al. Extreme risk category in the stratification system cardiovascular complications. The Journal of Atherosclerosis and Dyslipidemias. 2018; 4 (33): 8-16. (In Russ.)
18. Kukharchuk VV, Ezhov MV, Sergienko IV, et al. Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2020). Eurasian heart journal. 2020; 2: 6-29. (In Russ.) doi: 10.38109/ 2225-1685-2020-2-6-29.
19. Rozhkov DE, Tyrenko VV, Nikitin AE. The problem of achieving the target concentrations of low density lipoproteins cholesterol in real clinical practice: the data of the survey of doctors of different specialties. Therapy. 2021; 7(6): 62-71. (In Russ.) doi: 10.18565/therapy.2021.6.62-71.
20. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. The American journal of medicine. 2012; 125(9): 882-887.e1. doi: 10.1016/j.amjmed.2011.12. 013.
21. Bruckert E, Desamericq G, Khachatryan A, et al. Patient characteristics, treatment patterns, and adherence to lipid-lowering therapies following an acute coronary syndrome. Rev. Cardiovasc. Med. 2020; 21(4): 643–650. doi: 10.31083/j.rcm.2020.04.189.
22. Boytsov SA, Shakhnovich RM, Tereschenko SN, et al. The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. Kardiologiia. 2022; 62(7): 12-22. (In Russ.) doi: 10.18087/cardio.2022.7.n2051.
23. Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. American heart journal. 2005; 149(3): 464-473. doi: 10.1016/j.ahj. 2004.11.023.
24. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Journal of the American College of Cardiology. 2006; 48(3): 438-445. doi: 10.1016/j.jacc.2006.04.070.
25. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. Journal of the American College of Cardiology. 2008; 52(25): 2198-2205. doi: 10.1016/ j.jacc.2008.10.031.
26. Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. The Lancet. 2017; 390(10106): 1962-1971. doi:10.1016/S0140-6736(17) 32290-0.
27. Barbarash OL, Duplyakov DV, Zateischikov DA, et al. Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. Russian Journal of Cardiology. 2021; 26(4): 4449. (In Russ.) doi: 10.15829/1560-4071-2021-4449.
28. Staroverov II, Shakhnovich RM, Gilyarov MYu, et al. Eurasian clinical guidelines on diagnosis and treatment of acute coronary syndrome with st segment elevation (STEMI). 2020; 1: 4-77. (In Russ.) doi: 10.24411/2076-4766-2020-10001.
29. De Backer G, Jankowski P, Kotseva K, et al. Eurasian Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019; 285: 135-146. doi: 10.1016/j.atherosclerosis.2019.03.014.
30. Ray KK, Molemans B, Schoonen WM, et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. European Journal of Preventive Cardiology. 2021; 28(11): 1279-89. doi: 10.1093/eurjpc/zwaa047.
31. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European heart journal. 2020; 41(1): 111-188. doi: 10.1093/eurheartj/ehz455.
32. Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023; 28(5): 5471. (In Russ.) doi: 10.15829/1560-4071-2023-5471.
33. Visseren FL, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European journal of preventive cardiology. 2022; 29(1): 5-115. doi: 10.1093/eurjpc/zwab154.
34. Larina VN, Golovko MG, Larin VG. Modern possibilities of intensive treatment of dyslipidemia and gaps in its control: literature review. Cardiosomatics. 2022; 13(3): 168-175. (In Russ.) doi: 10.17816/CS133705.
35. Fonyakin AV, Geraskina LA. Lipid-lowering therapy and stroke prevention. Practical recommendations. Russian Medical Journal. 2015; 23(28): 1660-1664. (In Russ.)
36. Mareev VY. Evolution of approaches to the treatment of patients with atherogenic dyslipidemia (Lecture for doctors). Pharmacology and Pharmacotherapy. 2020; 2: 27-30. (In Russ.)
37. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine. 2023; 388: 1353-1364. doi: 10.1056/NEJMoa2215024.
38. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine. 2015; 372(25): 2387-2397. doi: 10.1056/NEJMoa1410489.
39. Chaulin AM, Mazaev AYu, Aleksandrov AG. The role of proprotein convertase subtilisin/kexin of type 9 (pcsk-9) in cholesterol metabolism and new opportunities of lipid corrective therapy. International Research Journal. 2019; 82(4): 124-126. (In Russ.) doi: 10.23670/IRJ.2019.82.4.025.
40. Khan SA, Naz A, Qamar Masood M, Shah R. Metaanalysis of inclisiran for the treatment of hypercholesterolemia. The American journal of cardiology. 2020; 134: 69-73. doi: 10.1016/j.amjcard.2020.08.018.
41. Konovalov GA, Bazhan SS. Evolocumab: innovative opportunities for LDL-C and Lp (a) lowering and cardiovascular risk management. Cardiology: News, Opinions, Training. 2017; 13(2): 45-46. (In Russ.)
42. Chaulin AM, Duplyakov DV. PCSK-9: modern views about biological role and possibilities of use as a diagnostic marker for cardiovascular diseases. Part 2. Cardiology: News, Opinions, Training. 2019; 2(21): 45-57. (In Russ.) doi: 10.24411/2309-1908-2019-12005.
43. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine. 2017; 376(18): 1713-1722. doi: 10.1056/nejmoa1615664.
44. Robinson JG, Jayanna MB, Bairey Merz CN, Stone NJ. Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C>100 mg/dl. PloS one. 2020; 15(10): e0240166. doi: 10.1371/journal.pone.0240166.
45. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. New England Journal of Medicine. 2018; 379: 2097-2107. doi: 10.1056/NEJMoa1801174.
46. Jukema JW, Szarek M, Zijlstra LE, et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. Journal of the American College of Cardiology. 2019; 74(9), 1167-1176. doi: 10.1016/j.jacc.2019.03.013.
47. The Russian Ministry of Health has approved a new drug for the treatment of hypercholesterolemia, evolocumab, produced by the biotechnological company Amgen. It is the world’s first approved PCSK9 enzyme inhibitor designed to lower blood cholesterol levels. Eurasian heart journal. 2017; 1: 62-63. (In Russ.)
48. Bulanova EYu. Statin therapy: evidence, expert opinion, perspective. General medicine. 2013; 3: 59-77. (In Russ.)
49. Pedersen TR. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. American Journal of Cardiovascular Drugs. 2010; 10: 10-7. doi: 10.2165/1158822-S0-000000000-00000.
50. Karagiannis AD, Liu M, Toth PP, et al. Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitors from molecular biology to clinical translation. Current atherosclerosis reports. 2018; 20(4): 20. doi: 10.1007/ s11883-018-0718-x.
